#car t cell

[spooniestrong]

View this post on Instagram

A post shared by Good News Movement (@goodnews_movement)

[sciencestyled]

Artemis and the Unintended Odyssey into Oncology

Let me, Artemis, goddess of the hunt, share with you a peculiar twist of fate that led me from the wild forests to the intricacies of modern science, specifically, the battle against cancer with CAR T-cell therapy. This tale starts on a seemingly ordinary day, marked by the mundane task of updating my celestial LinkedIn profile—a task even deities must bow to in the age of digital omnipresence.

It was while scrolling through the Olympian job board that I stumbled upon an advertisement seeking a "Dedicated Hunter of Malignant Foes." Mistaking this for a call to arms against a resurgence of mythic monsters, I promptly applied, envisioning epic battles against beasts of yore. Imagine my surprise when I discovered that the position was in a lab, not on a battlefield, and the foes were not creatures of flesh and blood but cancer cells!

Intrigued by this unexpected turn and ever the adaptable huntress, I decided to don the white coat of a researcher (a garb vastly different from my usual attire). My mission? To harness the mighty T-cells, turning them into specialized hunters known as CAR T-cells. These cells, I learned, were not unlike my hounds, trained to track and vanquish their quarry with precision.

The process, I must confess, involved less running through forests and more navigating the labyrinthine protocols of scientific research. Each step, from engineering the CAR T-cells to observing their relentless pursuit of cancer cells in petri dishes, was a new adventure—an academic hunt, if you will, with its own set of thrills and challenges.

What truly captivated me was the transformation of the T-cells. Much like my own transformation from deity to scientist, these cells were endowed with new powers, crafted through the magic of genetic engineering. They were equipped with a chimeric antigen receptor, a talisman that granted them the ability to see and attack cancer cells—cells that had, until then, hidden like cunning prey in the body’s vast wilderness.

Armed with this newfound knowledge and a burning curiosity, I authored the article "Artemis’s Quiver: Hunting Cancer with CAR T-cell Therapy" to share my unexpected odyssey. It was a humorous twist of fate that led me from celestial hunter to champion of cellular warriors, each of us adapting to our roles in this new age of discovery.

This, dear readers, is how I, Artemis, found myself at the crossroads of mythology and molecular biology, wielding pipettes as skillfully as arrows, in a quest not for glory, but for healing. It’s a wild tale, one that blends ancient myth with modern science, proving that even gods might venture into uncharted territories when the hunt calls for it.

[root-analysis]

CAR T Cell Therapy Market Size | Forecast (2035)

CAR T cell therapy is poised to reach USD 25 billion by 2035. This growth will occur at a steady annual rate of 20% from 2022 to 2035. The report from Roots Analysis thoroughly examines the current market size and the promising future of CAR T Cell Therapies market size. For more detailed information, access the report now!

[willowreader]

They may have found a way to cure autoimmune diseases. It is called CAR-T Cell Therapy.

[tankgotstuckinthecircusgate]

play with fire by the rolling stones is my roman empire tbh

[diginerve]

Pediatric Hematology-Oncology: Advances in Childhood Cancer Treatment

With time, many recent advances and developments have been made in Pediatric Hematology and oncology. Students often are short of time to track such recent findings, which can prevent them from becoming the best medical professionals. 

If we look at this branch of MD, we can see that many new ways of treating cancer have entered the field. All of these help children battle cancer easily. To make you aware of such recent developments, we are writing this blog post. 

Therefore, as a postgraduate, you must be aware of what is currently happening in the field of Pediatric Oncology. 

Latest advances in treating childhood cancer treatment

Over the last few decades, there have been many advances made in the field of Pediatrics and Hematology, which are discussed below:

CAR T Cell Therapy:

If you want to know about how to prevent childhood cancer with the newest and most personalized treatment, then CAR T Cell Therapy has all your answers. This Chimeric Antigen Receptor (CAR) T Cell Therapy is for kids who get leukemia back even after treatment. 

Radiation therapy:

Although Radiation therapy is another childhood cancer treatment, yet again, it is the talk of the town because newer and more precise ways of delivering radiation are being developed. In this therapy, cancer cells are destroyed with the help of high-energy X-rays, protons, and photons. It includes both external and internal radiation therapy. 

Precision medicine: 

The scope of treating childhood cancer goes beyond the universally applicable treatments mentioned above. In this approach, genetic analysis can find out the mutations causing a child’s cancer, which allows doctors to customize their treatment, which gives fewer side effects than chemotherapy.

Liquid biopsy: 

Another type of development made in childhood cancer treatment is Liquid biopsy. This minimally invasive technique allows doctors to quickly identify a kid's cancer cells. They do this by analyzing tumor DNA found in their blood. This can help them to give better treatment to the children when the cancer relapses again. 

By reading these discoveries, we can see that children can overcome cancer and come back to living healthier and happier lives than they used to live earlier. 

The following section is designed for postgraduate students who want to learn more about this field. 

Pediatrics MD— Course

This Pediatrics MD course at DigiNerve, designed by Dr. Piyush Gupta, helps students get all the latest and resourceful information they can't get elsewhere due to their time shortage. 

By enrolling in this MD in Pediatrics, students can get a range of benefits such as:

Online video lectures: The course includes 170+ hours of pediatrics video lectures.

Self-assessment questions: If you want to practice yourself and know where you stand, then you can try 1490+ MCQ questions outlined in the course.

Engagement activities: There are a range of activities, such as chat shows, journal clubs, and recent updates on the field.

AI chatbot: Dr. Wise (AI chatbot) can help you clarify all your theoretical and practical concepts.

So, if you want to stay updated with the latest information and advances in Pediatric Oncology, buy this course now!

Conclusion

Staying informed with the help of resources like this MD course led by qualified professionals like Dr. Piyush Gupta, you can pave the way towards becoming a medical professional and assist in creating a better and healthier future for children.

[archersgoon]

why did i write 900 words about lumatere what the fuck is going on

[hiero-green]

i get to draw part of an assignment for my advance therapy medicinal products class and i’m using t-cells to make jojo references ehgrhrgdhfbf

pray that i can actually get it finished for the 22nd,,, i don’t even have that much to do but my burnout is so bad rn

[regenhealthsolutions]

CAR-T cells can transfer antitumour immunity to other T cells by exchanging surface proteins

Novel research in cells and mice models has provided insight into the mechanisms that regulate trogocytosis, a process during which immune cells can exchange membrane-bound proteins. The study showed that chimeric antigen receptor cells (so-called CAR-T cells) could transfer tumour antigen-specific receptors to recipient T cells, and in doing so equipped the latter cells with tumour-targeting…

[bhaskarlive]

Immuneel launches affordable CAR T-cell therapy for non-Hodgkin’s Lymphoma in India

Bengaluru-based cell and gene therapy start-up Immuneel Therapeutics on Monday announced the launch of Qartemi — the country’s first personalised and precision therapy CAR T-cell therapy for treating B-cell Non-Hodgkin Lymphoma (B-NHL) in adults.

Source: bhaskarlive.in

[neosciencehub]

India approved a living drug to treat Blood Cancer

India approved a living drug to treat Blood Cancer @neosciencehub #India #BloodCancer #CDSCO #livingdrug #Qartemi #neosciencehub

For Indian patients with blood cancer who are at an advanced or relapsed stage of the disease, a “living drug” has been licensed. Patients with B-cell Non-Hodgkin Lymphoma (B-NHL) can now receive Qartemi, a CAR-T cell therapy, thanks to Immuneel Therapeutics, a biotech business based in Bengaluru. After the Central Drugs Standard Control Organization (CDSCO) authorized the indigenous NexCAR19,…

[janetushar1]

CAR T-Cell Therapy Market to Hit $5.9 Billion by 2032

What's Trending in CAR T-Cell Therapy Market?

- Keep Yourself Up-To-Date With The Latest Market Trends.

The global CAR T-Cell Therapy Market was valued at USD 2 Billion in 2024 and it is estimated to garner USD 5.9 Billion by 2032 with a registered CAGR of 14.6% during the forecast period 2024 to 2032.

Firstly, the Market report for CAR T-Cell Therapy Market describes the current state of the companies and recommends where it is likely to go next. The report shows the production, revenue, price, market share, and growth rate of each type, mainly divided into Product Types and Product Applications etc.

Additionally, this market report focuses on offering key business measures such as real market moves, market size, qualities, and freedoms, as well as forecast opportunities. This CAR T-Cell Therapy Market report also offers distinctive insights into wealthy regions such as Europe, North America, the Middle East, Africa, and Latin America.

Get a Sample Copy of the CAR T-Cell Therapy Market Report at: https://www.vantagemarketresearch.com/buy-now/car-tcell-therapy-market-2336/0

Top Competitors:

Celgene Corporation (U.S.), Cartesian Therapeutics Inc. (U.S.), Miltenyi Biotech (Germany), Autolus Therapeutics (UK), Caribou Biosciences Inc. (U.S.), Gilead Sciences Inc. (U.S.), Merck & Co. Inc. (U.S.), Intellia Therapeutics (U.S.), Juno Therapeutics Inc. (U.S.), Bristol-Myers Squibb (U.S.), Novartis AG (Switzerland), Bluebird Bio Inc. (U.S.), Sorrento Therapeutics Inc. (U.S.)

This market report has all the information you need to start or grow your business in the industry. It also includes market drivers, restraints, competitiveness, and geographic estimates, as well as a price and emerging market structure. It is a complete description of a company's business model, benchmarks, consumer preferences, value proposition, and net profit. This comprehensive CAR T-Cell Therapy Market study also sheds light on key techniques that help companies truly assess their customers' buying behavior.

It represents global economic trends between 2024 and 2032. With the help of this market research, top companies can easily make smarter financial decisions. This market analysis is an excellent technique to help companies implement new products. It also includes critical data on major industry topics, including market expansions and evolving market conditions.

This well-researched CAR T-Cell Therapy Market report describes the negative impact COVID-19 is having on various companies and offers companies recommendations on how to recover from the damage suffered by the outbreak as well as the nationwide quarantine. The plan analyzes the company's expectations and priorities, as well as the delivery of all crucial data.

You Can Buy This Report From Here: https://www.vantagemarketresearch.com/buy-now/car-tcell-therapy-market-2336/0

This report analyzes key market segments by type, application, and geography. The geographic analysis section covers key regions such as Europe, North America, the Middle East, Africa, and the Asia-Pacific region.

This CAR T-Cell Therapy Market report not only provides valuable data but outlines key goals, pricing strategies, and approaches to help market participants' recommendations in this report will make accelerating economic growth easy. It offers some specific tips and business-related data to help new competitors in the market grow their businesses and diversify their product lines. Companies in the industry should choose tactics that include new product launches, mergers, and partnerships to survive in the competitive marketplace and strengthen their position.

Regional Analysis

-North America [United States, Canada, Mexico]

-South America [Brazil, Argentina, Columbia, Chile, Peru]

-Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]

-Middle East & Africa [GCC, North Africa, South Africa]

-Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]

The quantitative information in this CAR T-Cell Therapy Market analysis helps predict future sales and market penetration. This type of information is based on statistics. The qualitative information provided here will greatly help the key players understand the buyer's opinion of your brand. Improving business goals becomes easy with the information provided in this report.

The industries can draw some conclusions about their original goals. In business. This CAR T-Cell Therapy Market research helps you make assumptions about your competition, customers, and the market in order to make informed business decisions. Additionally, it forecasts the competition in the market for the estimated period of 2024-2032. Effective decision-making in companies leads to business growth and is made possible by this precise market study.

Read Full Research Report with [TOC] @ https://www.vantagemarketresearch.com/industry-report/car-tcell-therapy-market-2336

Some of the Key Questions Answered in this Report:

Which are the five top players of the CAR T-Cell Therapy Market?

How will the CAR T-Cell Therapy Market change in the upcoming years?

Which product and application will take a share of the CAR T-Cell Therapy Market?

What will be the CAGR and size of the CAR T-Cell Therapy Market throughout the forecast period?

What are the drivers and restraints of the CAR T-Cell Therapy Market?

Which regional market will show the highest growth?

What is the current industry size, what will the market size be in 2030 and what will the growth rate be?

Who are the major competitors and what is their strategy?

What are the challenges to grow in the industry?

What are the market opportunities and challenges faced by the key vendors?

What are the barriers to entry for new players in the CAR T-Cell Therapy industry?

Check Out More Reports

Global Smart Thermostats Market:  Report Forecast by 2032

Global Dunnage Packaging Market: Report Forecast by 2032

Global Predictive Maintenance Market: Report Forecast by 2032

Global WPA LSG and FT and NMS Market: Report Forecast by 2032

Global Digital Agriculture Market: Report Forecast by 2032

[root-analysis]

CAR T Cell Therapy Market Size, Share, Trends, and Forecast (2035)

CAR T cell therapy is poised to reach USD 25 billion by 2035. This growth will occur at a steady annual rate of 20% from 2022 to 2035. The report from Roots Analysis thoroughly examines the current market size and the promising future of CAR T Cell Therapies companies market size. For more detailed information, access the report now!

[indiacancersurgerysite]

👨‍⚕💉💊🩺 Affordability of CAR-T cell therapy cost in India is generally lower than in many Western countries, primarily due to reduced operational expenses, including labor and infrastructure costs.👨‍⚕💉💊🩺

[drgauravkharya]

Dr Gaurav Kharya" Advancing Pediatric Cancer Treatment: CAR T Cell Therapy with Dr. Gaurav Kharya"

Dr Gaurav Kharya Best Doctor for Children’s Cancer in Delhi – Redefining Pediatric Oncology with CAR T Cell Therapy

Pediatric cancer treatment has entered a new era, with revolutionary therapies offering more targeted, effective solutions. Among the most promising advancements is CAR T cell therapy, an innovative immunotherapy that is transforming outcomes for children battling cancer. Spearheading this breakthrough in India is Dr. Gaurav Kharya, one of the most trusted and experienced specialists in pediatric oncology, hematology, and immunology. His dedication to providing top-tier care ensures that young patients have access to the latest in cancer treatment.

What Makes CAR T Cell Therapy a Game Changer?

CAR T cell therapy is a form of personalized medicine that reprograms a patient’s T cells to better recognize and eliminate cancer cells. T cells, a type of white blood cell, are extracted from the patient and genetically engineered to express chimeric antigen receptors (CARs). These specialized receptors enable the T cells to locate and attack cancer cells with precision. Once the T cells are reintroduced into the patient’s body, they continuously patrol for cancer cells, even after the primary treatment is complete.

The therapy's ability to target cancer cells while sparing healthy tissues makes it a less invasive option than conventional treatments like chemotherapy and radiation. In many cases, CAR T cell therapy has led to complete remission for patients with certain types of blood cancers, particularly leukemia and lymphoma. This "living drug" approach offers long-lasting protection, as the engineered T cells remain vigilant, significantly reducing the chances of a relapse.

Dr. Gaurav Kharya: A Pioneer in Pediatric CAR T Cell Therapy

As one of the leading doctors for children’s cancer treatment in Delhi, Dr. Gaurav Kharya has made significant contributions to the adoption of CAR T cell therapy in India. With over two decades of experience and more than 1000 successful bone marrow transplants, Dr. Kharya is a renowned expert in pediatric hematology and oncology. His expertise in CAR T cell therapy has allowed many young cancer patients to access this life-saving treatment, providing them with a brighter future.

In his role as the Senior Consultant in Pediatric Hematology, Oncology & Immunology at Apollo Hospitals, Delhi, Dr. Kharya works closely with families to provide tailored, compassionate care. His leadership in immunotherapy and bone marrow transplants ensures that children receive the best possible treatment options, guided by the latest global advancements in cancer care.

The Impact of CAR T Cell Therapy on Pediatric Blood Cancers

CAR T cell therapy has shown remarkable success in treating acute lymphoblastic leukemia (ALL), one of the most common forms of cancer in children, as well as non-Hodgkin lymphoma. These cancers, which often resist traditional treatments, have seen impressive remission rates thanks to CAR T cell therapy. For families facing a pediatric cancer diagnosis, this therapy offers renewed hope, as it targets cancer at its source while minimizing harmful side effects.

Expanding the Reach of CAR T Cell Therapy in India

While CAR T cell therapy is widely recognized and used in the United States and Europe, its availability in India is still growing. However, with experts like Dr. Gaurav Kharya leading the charge, this therapy is becoming increasingly accessible to children across the country. By working with top medical institutions, Dr. Kharya is helping to bring this breakthrough treatment to Indian families, ensuring that they no longer have to travel abroad for advanced cancer care.

Looking to the future, researchers and clinicians like Dr. Kharya are exploring the potential of CAR T cell therapy for treating solid tumors, expanding its use beyond blood cancers.

Why Choose Dr. Gaurav Kharya for Pediatric Cancer Treatment?

When it comes to treating children’s cancers, experience, expertise, and empathy are paramount. Dr. Gaurav Kharya stands as a beacon of hope for families, combining his medical proficiency with a compassionate approach to patient care. His deep involvement in bone marrow transplants, immunotherapy, and CAR T cell therapy positions him as one of the best doctors for children’s cancer in Delhi.

With a strong commitment to staying at the forefront of pediatric oncology, Dr. Kharya’s work continues to change the lives of countless children and their families, offering them the best chance at overcoming cancer.

Conclusion

CAR T cell therapy is reshaping the landscape of pediatric cancer treatment, offering new hope where traditional treatments fall short. Under the expert care of Dr. Gaurav Kharya, children in India now have access to this life-changing therapy. As one of the leading pediatric oncologists in Delhi, Dr. Kharya ensures that each child’s health is prioritized, with personalized, state-of-the-art care that makes a real difference.